Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

[News]

Synta Pharmaceuticals Corp. announced today that interim results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy Foundation Symposium in New York City on Friday, November 9 during the 11:45 a.m. session on new agents for lung cancer. Presenting this data at the conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University.

More... (http://www.news-medical.net/news/20121107/Synta-announces-interim-results-from-docetaxel-Phase-2b3-trial-on-NSCLC.aspx)